A better pricing environment in the US, impending product launches, and prospects of superior profitability are also seen boosting the earnings of the company going ahead, analysts said.
Gland Pharma surges 20% as biz momentum seen turning
Date:
A better pricing environment in the US, impending product launches, and prospects of superior profitability are also seen boosting the earnings of the company going ahead, analysts said.
Popular
© USA Intervierwer. All Rights Reserved.